July 16, 2024Nature CommunicationsOpen Access

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

View Full Paper

Ask AI

Bookmark

Authors

OSOlivia Le SauxUniversité Claude Bernard Lyon 1 MAMaude ArdinUniversité Claude Bernard Lyon 1 JBJustine BerthetUniversité Claude Bernard Lyon 1

Discussion

Member takes

Implication

Randomized trial reveals biomarkers of response to neoadjuvant chemotherapy and pembrolizumab in ovarian carcinoma, suggesting endothelial targeting may reverse resistance.

Key Points

Positive response to neoadjuvant chemotherapy plus pembrolizumab correlates with elevated CD8B/FOXP3 expression ratios, overcoming immunoresistance in ovarian carcinoma.
An area under the curve of 0.93 confirms that combining endothelial cells and monocyte gene signatures with immune ratios predicts response to pembrolizumab treatment.
Randomized phase II trial exploratory analysis tracked paired patient samples using RNA-seq, profiling tumor shifts during neoadjuvant chemotherapy and pembrolizumab.
Highlights that targeting regulatory T cells and VEGFR2 positive endothelial cells may overcome immunoresistance, guiding novel therapeutic strategies in ovarian carcinoma.

Cite This Study

Saux et al. (2024) studied this question.

synapsesocial.com/papers/68e6012eb6db643587594d22 https://doi.org/10.1038/s41467-024-47000-5

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals biomarkers of response to neoadjuvant chemotherapy and pembrolizumab in ovarian carcinoma, suggesting endothelial targeting may reverse resistance.

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider